Sponsored

Radiopharm Theranostics (ASX: RAD) inks AU$12.5M share facility agreement with Lind

February 06, 2024 07:12 AM IST | By Sonal Goyal
 Radiopharm Theranostics (ASX: RAD) inks AU$12.5M share facility agreement with Lind
Image source: Company website

Highlights

  • Lind Partners, a US institutional investor, has invested up to AU$12.5 million in Radiopharm.
  • Under a share subscription agreement, the company will receive AU$1.2 million, and under a share purchase agreement, it will receive further AU$11.3 million.
  • The share purchase agreement is a staged placement.
  • Funds would aid the company’s clinical trial pipeline.

Radiopharm Theranostics Limited (ASX: RAD) has entered into a share subscription agreement and a share purchase agreement with Lind Global Fund II, LP, managed by US-based The Lind Partners.

The share subscription agreement provides a funding of AU$1.2 million, while the share purchase agreement is a staged placement of up to AU$11.3 million. Under the share purchase agreement, the funding will be provided through monthly instalments of AU$50k to AU$1 million, over an initial period of 12 months. The first instalment will be of AU$300,000.

The funds will be used to advance the company’s clinical trial pipeline.

Lind Partners invests in small and mid-cap companies which publicly trade in Australia, the UK, the US and Canada.

RAD shares traded at AU$0.064 apiece at the time of writing on 6 February 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.